Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)

被引：0

作者：

Araki, Tomonori ^{[1
]}

Sonoda, Yuki ^{[1
]}

Shimokawa, Mototsugu ^{[2
,3
]}

Otsuka, Taiga ^{[4
]}

Hayashi, Kohei ^{[1
]}

Honda, Takuya ^{[1
]}

Nakao, Kazuhiko ^{[1
]}

Shibuki, Taro ^{[5
,6
]}

Nakazawa, Junichi ^{[7
]}

Arima, Shiho ^{[8
]}

Miwa, Keisuke ^{[9
]}

Okabe, Yoshinobu ^{[10
]}

Koga, Futa ^{[11
]}

Ueda, Yujiro ^{[12
]}

Kubotsu, Yoshihito ^{[13
]}

Shimokawa, Hozumi ^{[14
]}

Takeshita, Shigeyuki ^{[15
]}

Komori, Azusa ^{[16
,17
]}

Nishikawa, Kazuo ^{[16
]}

Otsu, Satoshi ^{[16
]}

Hosokawa, Ayumu ^{[18
]}

Oda, Hisanobu ^{[19
]}

Sakai, Tatsunori ^{[20
]}

Arita, Shuji ^{[21
]}

Kawahira, Machiko ^{[22
]}

Taguchi, Hiroki ^{[23
,24
]}

Tsuneyoshi, Kengo ^{[23
]}

Kawaguchi, Yasunori ^{[25
]}

Fujita, Toshihiro ^{[26
]}

Sakae, Takahiro ^{[26
]}

Shirakawa, Tsuyoshi ^{[27
,28
]}

Mizuta, Toshihiko ^{[29
]}

Mitsugi, Kenji ^{[30
]}

机构：

[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, Nagasaki, Japan

[2] Natl Kyushu Canc Ctr, Clin Res Inst, Fukuoka, Japan

[3] Yamaguchi Univ, Grad Sch Med, Dept Biostat, Yamaguchi, Japan

[4] Minato Med Clin, Dept Internal Med, Fukuoka, Japan

[5] Natl Canc Ctr Hosp East, Dept Promot Drug & Diagnost Dev, Div Drug & Diagnost Dev Promot, Translat Res Support Off, Chiba, Japan

[6] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Chiba, Japan

[7] Kagoshima City Hosp, Dept Med Oncol, Kagoshima, Japan

[8] Kagoshima Univ, Grad Sch Med & Dent Sci, Digest & Lifestyle Dis, Kagoshima, Japan

[9] Kurume Univ Hosp, Multidisciplinary Treatment Canc Ctr, Kurume, Fukuoka, Japan

[10] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Fukuoka, Japan

[11] Saga Med Ctr Koseikan, Dept Pathol, Saga, Japan

[12] Japanese Red Cross Kumamoto Hosp, Dept Paediat, Kumamoto, Japan

[13] Karatsu Red Cross Hosp, Dept Internal Med, Saga, Japan

[14] Kyushu Hosp, Japan Community Healthcare Org, Fukuoka, Japan

[15] Japanese Red Cross Nagasaki Genbaku Hosp, Dept Gastroenterol, Nagasaki, Japan

[16] Oita Univ, Fac Med, Dept Med Oncol & Hematol, Oita, Japan

[17] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Ehime, Japan

[18] Univ Miyazaki Hosp, Dept Clin Oncol, Miyazaki, Japan

[19] Saiseikai Kumamoto Hosp, Div Integrat Med Oncol, Kumamoto, Japan

[20] NHO Kumamoto Med Ctr, Dept Med Oncol, Kumamoto, Japan

[21] Miyazaki Prefectural Miyazaki Hosp, Dept Chemotherapy, Miyazaki, Japan

[22] Kagoshima Kouseiren Hosp, Dept Gastroenterol, Kagoshima, Japan

[23] Izumi Gen Med Ctr, Dept Gastroenterol, Kagoshima, Japan

[24] Kagoshima City Hosp, Dept Gastroenterol, Kagoshima, Japan

[25] Asakura Med Assoc Hosp, Dept Gastroenterol, Asakura City, Japan

[26] Saiseikai Sendai Hosp, Dept Gastroenterol, Kagoshima, Japan

[27] Oncol Treatment Study Grp, Clin Hematol, 1-14-6 Muromi Gaoka,Nishi Ku, Fukuoka, Fukuoka 8190030, Japan

[28] Eikoh Hosp, 3-8-15 Befu Nishi, Shime, 8112232, Japan

[29] Fujikawa Hosp, Dept Internal Med, Saga, Japan

[30] Sasebo Kyosai Hosp, Dept Med Oncol, Sasebo, Japan

来源：

SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期

关键词：

CHEMOTHERAPY-INDUCED NEUTROPENIA; CELL LUNG-CANCER; PANCREATIC-CANCER; LIPOSOMAL IRINOTECAN; COLORECTAL-CANCER; SURVIVAL; FLUOROURACIL; GEMCITABINE; TRIAL;

D O I：

10.1038/s41598-025-88005-4

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The relationship between nanoliposomal irinotecan/fluorouracil/leucovorin (NFF) treatment outcomes and neutropenia in patients with pancreatic cancer has not been thoroughly examined. Thus, we conducted a retrospective analysis of data from patients with pancreatic cancer who were treated with NFF to investigate this relationship. Neutropenia was assessed according to the Common Terminology Criteria for Adverse Events across three cutoffs: A (grade 0 versus grade 1-4), B (grades 0-1 versus 2-4), and C (grades 0-2 versus 3-4). The primary endpoint was overall survival (OS), and the secondary endpoints were overall response rate, progression-free survival (PFS), and relative dose intensity. Of the 161 patients, 93, 8, 22, 30, and 8 patients had neutropenia of grades 0, 1, 2, 3, and 4, respectively. The overall response rates differed significantly at cutoff C (p = 0.02), with the odds ratio for cutoff C being the highest, followed by cutoffs B and A. Significant differences in OS were observed at cutoffs A (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.44-0.94; p = 0.02) and B (HR, 0.63; 95% CI, 0.43-0.92, p = 0.02). Similarly, PFS showed significant differences at cutoffs A and B (p < 0.01). NFF-induced neutropenia can be a useful prognostic factor for patients with pancreatic cancer.

引用

页数：12

共 43 条

[1] Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia
Ahn, Shin
Lee, Yoon-Seon
Chun, Yun-Hee
Kwon, In-Ho
Kim, Won
Lim, Kyung Soo
Kim, Tae Won
Lee, Kyoo-Hyung
[J]. SUPPORTIVE CARE IN CANCER, 2011, 19 (08) : 1151 - 1158
[2] A CONFIDENCE-INTERVAL FOR THE MEDIAN SURVIVAL-TIME
BROOKMEYER, R
CROWLEY, J
[J]. BIOMETRICS, 1982, 38 (01) : 29 - 41
[3] Chiang NJ, 2022, AM J CANCER RES, V12, P5062
[4] Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study
Chiu, Tai-Jan
Su, Yung-Yeh
Yang, Shih-Hung
Li, Chung-Pin
Bai, Li-Yuan
Chiang, Nai-Jung
Chuang, Shih-Chang
Shan, Yan-Shen
Chan, De-Chuan
Chen, Li-Tzong
Yen, Chia-Jui
Peng, Cheng-Ming
Chen, Yen-Yang
Chen, Jen-Shi
Chou, Wen-Chi
[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[5] Common Terminology, Criteria for Adverse Events (CTCAE)
[6] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, Thierry
Desseigne, Francoise
Ychou, Marc
Bouche, Olivier
Guimbaud, Rosine
Becouarn, Yves
Adenis, Antoine
Raoul, Jean-Luc
Gourgou-Bourgade, Sophie
de la Fouchardiere, Christelle
Bennouna, Jaafar
Bachet, Jean-Baptiste
Khemissa-Akouz, Faiza
Pere-Verge, Denis
Delbaldo, Catherine
Assenat, Eric
Chauffert, Bruno
Michel, Pierre
Montoto-Grillot, Christine
Ducreux, Michel
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
[7] Dale David C, 2009, Curr Opin Support Palliat Care, V3, P207, DOI 10.1097/SPC.0b013e32832ea6ae
[8] Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials
Di Maio, M
Gridelli, C
Gallo, C
Shepherd, F
Piantedosi, FV
Cigolari, S
Manzione, L
Illiano, A
Barbera, S
Robbiati, SF
Frontini, L
Piazza, E
Ianniello, GP
Veltri, E
Castiglione, F
Rosetti, F
Gebbia, V
Seymour, L
Chiodini, P
Perrone, F
[J]. LANCET ONCOLOGY, 2005, 6 (09) : 669 - 677
[9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Eisenhauer, E. A.
Therasse, P.
Bogaerts, J.
Schwartz, L. H.
Sargent, D.
Ford, R.
Dancey, J.
Arbuck, S.
Gwyther, S.
Mooney, M.
Rubinstein, L.
Shankar, L.
Dodd, L.
Kaplan, R.
Lacombe, D.
Verweij, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
[10] Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Frampton, James E.
[J]. DRUGS, 2020, 80 (10) : 1007 - 1018

← 1 2 3 4 5 →